Abstract: Hydantoins and their derivatives constitute a group of pharmaceutical compounds with anticonvulsant and antiarrhythmic properties, and are also used against diabetes. N-3 and C-5 substituted imidazolidines are examples of such products. As such, we have developed a synthesis of 2,4-dione and 2-thioxo-4-one imidazolidinic derivatives by reaction of amino acids with C-phenylglycine, phenyl isocyanate and phenyl isothiocyanate. Four amino-derivatives IG(1-4) and eight imidazolidinic derivatives, IM(1-8), were obtained in yields of 70-74%. The mass, infrared, 1 H and 13 C-NMR spectra of representative products are discussed.
Introduction
Nowadays, there is an incessant search for biological functional compounds suitable for treating diverse illnesses. The development of more efficient and less toxic products often involves the study of new synthetic routes or structural modifications of existing molecules and medicinal drugs are often manufactured by modification or molecular variation using bioisosterism [1] . The influence of an atom or an atom group modification by bioisosters can be analyzed based on the biological activity presented by the drug, having an identical or exact antagonistic effect. The synthesis of heterocyclic 2,4-imidazolidinones or hydantoins (1) has been studied intensively for their important pharmacological properties [2] . Substances that contain these heterocyclic moieties present significant biological activities as antifungal [3] , antibacterial and anti-inflammatory [4] drugs, for the treatment of hypoglycemia [5] , or as plant growth inhibitors [6] , among other properties. Thiohydantoins are sulfur analogs of hydantoins with one or two carbonyl groups replaced by thiocarbonyl groups. The 2-thiohydantoins have been widely evaluated due to their applications as hypolipidemic, anticarcinogenic, antiviral (e.g., herpes virus, HSV, HIV and tuberculosis), antimicrobial, anti-ulcer and anti-inflammatory agents [7] .
Several studies [8] [9] [10] have described the synthesis of amino acid compounds, their importance and applications as intermediates for the synthesis of heterocyclics [11, 12] . The present study aimed to contribute with the chemical and pharmacological studies of imidazolidinic compounds, whereby imidazolidinic bioisosters obtained from amino acids were synthesized and characterized as imidazolidin-2,4-dione and 2-thioxo-imidazolidin-4-one derivatives. Among the compounds synthesized we evaluated 3-phenyl-5-(4-isopropylphenyl)-imidazolidin-2,4-dione (IM-7), and a focus of this study was to investigate the acute cardiovascular effects induced by IM-7 in rats. In addition, the effects of 5-(4-ethylphenyl)-3-phenylimidazolidin-2,4-dione (IM-3) on the Central Nervous System was investigated, and its possible involvement in antinociception was considered based on results obtained with early pharmacological screening [13] .
Results and Discussion
Eight 3,5-di-substituted-imidazolidinic compounds were obtained in 70-74% yield by means of amino acids via Strecker synthesis. Of these imidazolidinic compounds, one (IM-5) was previously reported [14] , but its structure was not elucidated by the usual physical techniques. All samples were obtained in two steps: first, a Strecker synthesis was performed using sodium cyanide, ammonium chloride and 4-arylaldehydes, followed by an acid hydrolysis to form the corresponding C-arylglycine derivative (IG). C-4-Methoxyphenylglycine (IG-1), C-4-ethylphenylglycine (IG-2), C-4-methylphenylglycine (IG-3) and C-4-isopropylphenylglycine (IG-4) were thus obtained. In the second part, the amino acids reacted with phenyl isocyanate or phenyl isothiocyanate, followed by an acid hydrolysis reaction (Scheme 1). Eight imidazolidinic compounds (IM) were thus obtained: ' '
Mass spectral data support the proposed structures. Scheme 2 shows the fragmentation pattern for 3-phenyl-5-(4-methylphenyl)-imidazolidin-2,4-dione (IM-1) which serves as an example for all the compounds mutatis mutandis. Table 1 ). The significant 13 C-NMR spectra signals are listed in Table 2 and are in agreement with the proposed structures. The pharmacological studies, in vivo, with non-anesthetized rats, IM-7 (1, 5, 10, 20, 30 mg/kg, i.v.) induced hypotension (-3.6 ± 1.6, -4.2 ± 1.4, -4.4 ± 1.6, -24.6 ± 10.9, -32 ± 9.2 %). Compound IM-7 (20, 30 mg/kg, i.v.) also induced bradycardia (-28 ± 15, -50 ± 15 %). Both responses were completely abolished in rats treated with atropine (2 mg/Kg, i.v.). In mesenteric rings IM-7 (10 The present study showed that treatment of mice with 5-(4-ethylphenyl)-3-phenylimidazolidin-2,4-dione IM-3 in doses of 250 and 500 mg/kg, i.p caused a significant decrease in writhing numbers after administration (7.3 ± 2.3; 3.6 ± 1.7, respectively) in relation to control (22.1 ± 6.0), indicating a antinociceptive effect, however, the central depressant effect was not confirmed because this compound did not increase the response time in the Hot Plate Test in comparison with a standard drug (morphine 6 mg/kg, i.p).
Experimental

General
Mass spectra were obtained using a Finnigan GCQ Mat type quadrupole-ion trap spectrometer. IR spectra were obtained by means of a Bruker IFS66 spectrometer with the samples in KBr discs. 1 
General method for the preparation of C-arylglycines
Appropriate amounts of KCN and ammonium chloride were dissolved in distilled H 2 O (100 mL). Equimolar quantities of the arylaldehyde in MeOH (100 mL), were added under vigorous stirring and the reaction continued for 120 minutes. H 2 O (250 mL) was added and the resulting mixture was then added to toluene (250 mL). The toluene phase was separated and then extracted with HCl (6N, 3 × 100 mL). The combined acid extract was refluxed for 8 hours, giving the desired product in the form of white crystals after cooling. These were filtered off, washed with CHCl 3 and air-dried. 
(±)C-(4-Methoxyphenyl)glycine (IG-1
)
General method for the preparation of 3-phenyl-5-arylimidazolidinic derivatives
C-Arylglycine was dissolved in the minimum amount of aqueous NaOH (10%) with stirring which was continued for an additional 120 minutes. Equimolar quantities of the required phenyl isocyanate or phenyl isothiocyanate was added in small amounts and stirring continued for a further 4 h. After 24 hours the precipitate was separated by filtration and the remaining solution was acidified with HCl. The aroylimidazilidinic acid obtained was refluxed for 1 h with 40 mL of 6N HCl solution. The white crystalline product was filtered off, washed with H 2 O, air-dried and recrystallized from ethanol/H 2 O (1:1). 
(±)-3-Phenyl-5-(4-methylphenyl)-imidazolidine-2,4-dione (IM-1). C-4-
(±)3-Phenyl-5-(4-ethyphenyl)-imidazolidine-2,4-dione (IM-3). C-4-Ethylphenylglycine
Conclusions
Four new C-phenylglycine derivatives IG(1-4) containing different groups and obtained via Strecker synthesis were subjected to reactions with phenyl isocyanate and phenyl isothiocyanate to furnish eight imidazolidinic compounds IM (1-8) , seven of which were new, and one, IM-5, whose structure was not previously elucidated. Their structures were confirmed by infrared, 1 H-and 13 C-NMR and mass spectroscopies. The pharmacological studies with IM-3 and IM-7 show that these compounds are bioactive structures. In the cardiovascular system IM-7 induced a marked hypotension and bradycardia which are probably due to decrease of the peripheral resistances. Likewise in vivo, the relaxant effect of this compound seems to involve endothelial muscarinic receptor activation and consequent NO release. The results obtained with pharmacological and behavior tests suggest that IM-3 showed peripheral antinociceptive effect considering the negative results in the Hot Plate test.
